Reduced plasma phosphatidylethanolamines in e-cigarette, or vaping, product use-associated lung injury (EVALI).

McGraw, Matthew D; Croft, Daniel P; Nacca, Nicholas E; Rahman, Irfan

McGraw, Matthew D; Croft, Daniel P; Nacca, Nicholas E; Rahman, Irfan.

Afiliación

McGraw MD; Department of Pediatrics, Division of Pediatric Pulmonology, University of Rochester Medical Center, Rochester, New York, USA.
Croft DP; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Nacca NE; Department of Medicine, Division of Pulmonary Critical Care, University of Rochester Medical Center, Rochester, New York, USA.
Rahman I; Department of Toxicology, University of Rochester Medical Center, Rochester, New York, USA.

Pediatr Pulmonol ; 57(5): 1350-1354, 2022 05.

Article en En | MEDLINE | ID: mdl-35233972

Asunto(s)

Sistemas Electrónicos de Liberación de Nicotina; Lesión Pulmonar; Vapeo; Dronabinol; Humanos; Lesión Pulmonar/inducido químicamente; Fosfatidiletanolaminas; Vapeo/efectos adversos

Palabras clave

EVALI; e-cigarette; lung; phosphatidylethanolamines; plasmalogens

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Lesión Pulmonar / Sistemas Electrónicos de Liberación de Nicotina / Vapeo Tipo de estudio: Risk_factors_studies Idioma: En Revista: Pediatr Pulmonol Asunto de la revista: PEDIATRIA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google